Feasibility of Assessing Lymphoma Response to Precise Local Injection of Candidate Chemotherapy Agents

Inclusion Criteria:

• 18 years of age or over
• Has enlarged lymph node(s) highly suspicious of lymphoma; or has been diagnosed with lymphoma but is untreated; or has persistent recurrent, or progressive lymphoma
• At least one enlarged lymph node that is considered accessible for percutaneous injection by the investigator and that is at least 2 cm in longest dimension.
• ECOG performance status of 0-2 (or a Karnofsky performance status of >50%).
• Labs required for enrollment: Absolute neutrophil count > 1000/mm3, platelet count > 50,000/mm3, hematocrit > 25%, creatinine <3.0 mg/dl, total bilirubin <4.0 mg/dl, SGOT and SGPT less than five times the institutional upper limits of normal.

Exclusion Criteria:

• Lymphoma patients in which the delay of surgery until the lymph node resection date or other factors associated with the study are not feasible.
• Patients with central nervous system disease.
• Any therapy that is potentially immunosuppressive or has anticancer activity in the 4 weeks prior to device microinjection.
• Patients with active fungal, viral, or bacterial infections
• Pregnant women.
• Inability to give informed consent.